Accelerate The Translation Of Novel Approaches To Target RAS- Driven Tumours With Meaningful Therapeutic Applications

Finally Drugging The "Undruggable" RAS

After three decades of trial and error to target the driver of 30% of all diagnosed cancers, scientists are finally making meaningful clinical progression to target the cancer master switch, the RAS family of proteins.

The RAS- Targeted Drug Discovery Summit Europe is the only industry and translational focused platform dedicated to bringing you innovative anti-RAS drug discovery science, capturing the most pioneering data, thought-provoking insights and practical lessons learned, enabling you to maximise the clinical therapeutic window of your anti-RAS candidate.

With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, join the RAS- Targeted Drug Discovery Summit Europe to gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic.

See all pricing and early booking discounts here.

Meet Our World-Class Speaker Faculty

Hear What Our 2019 Attendees Said

REVOLUTION Medicines logo

"The meeting content successfully captured the latest goings on in the field, and brought together all the key players in a setting that encouraged interaction."

James Aggen, Senior Director - Medicinal Chemistry, Revolution Medicines

Blueprint Medicines Logo

“Cutting-edge science and transformative medicine presented and discussed in a stimulating environment."

Zhigang Weng, Director - Biology, Blueprint Medicines

Companies Already Confirmed To Attend Include

Who Will You Meet?

2020 Confirmed Partner

Other Events In The Undruggable Series